Crossmark

Rare and common variants in ERAP1 and ERAP2 selected for in response to Yersinia pestis infection contribute to autoimmune disease including inflammatory bowel disease

Crossref DOI link: https://doi.org/10.1007/s00335-025-10183-3

Published Online: 2025-12-22

Published Print: 2026-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Win, Lynn K. https://orcid.org/0000-0002-2624-0390
Cheng, Guo

Ashton, James J.

Kadhim, Alex Z.

Green, Zachary

Beattie, R. Mark

Ennis, Sarah
Funding

Funding for this research was provided by:

Southampton NIHR Biomedical Research Centre – Data, Health & Science theme

NHS Genomic AI network (GAIN) of excellence

EPSRC funding on AI health research ((EP/Y01720X/1))
License Information

Text and Data Mining valid from 2025-12-22

Version of Record valid from 2025-12-22
More Information

Article History

Received: 18 July 2025

Accepted: 1 December 2025

First Online: 22 December 2025

Declarations

:

: JJA is a scientific advisory board member for Orchard Therapeutics. The remaining authors declare no conflicts of interest in relation to the submitted work.

: The study was approved by Southampton and South-West Hampshire Research Ethics Committee (09/H0504/125). At the time of recruitment, written informed consent was provided by patients and/or their parents/legal guardians.

Document is current

Any future updates will be listed below